GOG-0264

Terminated

Return to Protocol Table

A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

Principal Investigator

Jubilee Brown, MD

Status

Terminated

Open to Accrual

February 8, 2010

Closed to Accrual

June 12, 2020

Closed to Accrual & Treatment

June 12, 2020

Terminated

October 11, 2024


Disease Site

Gynecologic [GY] Ovarian

Phase

II

Developmental Therapeutics

No

Primary Objective

To assess the activity of paclitaxel and carboplatin with respect to progression free survival (using bleomycin, etoposide, and cisplatin (BEP) as a reference) for newly diagnosed advanced or recurrent chemonaive ovarian sex cord-stromal tumors.

Patient Population

Paclitaxel and carboplatin with respect to progression free survival (using bleomycin, etoposide, and cisplatin (BEP) as a reference) for newly diagnosed advanced or recurrent chemonaive ovarian sex cord-stromal tumors.

Target Accrual

128

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.